^
Association details:
| Biomarker: | CCNA2 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | BI2536 (PLK1 inhibitor, BRD4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pharmacogenomic Analysis Reveals CCNA2 as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric Cancer
Published date:
05/30/2020
Excerpt:
We discovered that expression of CCNA2, encoding cyclin A2, was commonly associated with responses to polo-like kinase 1 (PLK1) inhibitors (BI-2536 and volasertib). Our study suggests that CCNA2 is a novel biomarker predictive of sensitivity to PLK1 inhibitors for the treatment of advanced gastric cancer, particularly cases carrying KRAS mutation.
DOI:
10.3390/cancers12061418
